Acknowledgements

Funding of ISAAC Phase One

ISAAC was open to any collaborator who agreed to adhere to the protocol. Countries in which there was little existing information about asthma, rhinoconjunctivitis and eczema were particularly encouraged to participate. Each centre was responsible for obtaining its own funding. There were many field workers and funding agencies who supported data collection and national, regional and international meetings, including the meetings of the ISAAC Steering Committee. Unfortunately, these are too numerous to mention and are acknowledged elsewhere in local publications.

The ISAAC International Data Centre was funded by:

The Health Research Council of New Zealand,
The Asthma and Respiratory Foundation of New Zealand,
The National Child Health Research Foundation,
The Hawke's Bay Medical Research Foundation,
The Waikato Medical Research Foundation,
Glaxo Wellcome New Zealand
Astra New Zealand.

Glaxo Wellcome International Medical Affairs funded the regional co-ordinating centres.

Funding of ISAAC Phase Two

The coordination and central laboratory analyses of the European centres were funded by the Fifth Framework Programme of European Commission (QLK4-CT-1999-01288).
The following bodies funded the local studies.

Spain: (Almeria, Cartagena, Madrid, Valencia): Fondo de Investigacion Sanitaria (grant code 00/1092E).
Turkey: (Ankara): Scientific and Technical Research Council of Turkey (grant code SPAG-2237),; Treatment and Research Foundation of Turkey for Allergy, Asthma and Immunology,; The Research foundation of Hacettepe University, Faculty of Medicine.
Greece: (Athens, Thessaloniki): The Thorax Foundation Research Center.
France: (Créteil): French Institute of Health and Medical Research (Institut National de la Santé et de la Recherche Médicale (INSERM), grant code IDS 337/4D001D and 737/69480),; Ministère de l'Emploi et de la Solidarité (grant code 227/7HL02D),; Mutuelle Générale de l'Education Nationale (grant code 257/8PL01F),; Agence de l’Environnement et de la Maitrise de l’Energie ADEME/PRIMEQUAL 96 (grant code FJ012B).
Germany: (Dresden, Munich, Ulm): German Ministry of Education and Research (grant code 01 EE 9411-3; Dresden, Munich),; Rudolf and Clothilde Eberhardt-Foundation (Ulm).
Italy: (Rome): Lazio Regional Health Authority.
New Zealand: (Hastings): Health Research Council of New Zealand,; Asthma and Respiratory Foundation of New Zealand,; Hawkes Bay Medical Research Foundation.
Sweden: (Linköping, Östersund): The Swedish Foundation for Health Care Sciences and Allergy Research.
India: (Mumbai): Jaslok Hospital & Research Centre.
West Bank: (Ramallah): Al-Quds University, Directorate General for International Cooperation and Belgian Technical Cooperation.
The Netherlands: (Utrecht): Dutch Ministries of the Environment, of Health and of Transport.
UK: (West Sussex): South Thames National Health Service Regional and Development project SPGS.

The centres in Mumbai, Ankara, Kintampo (Ghana), Riga (Latvia), Tallinn (Estonia), Tblisi (Georgia) and Tirana (Albania) were supported, at least in part, by European members of the ISAAC Steering Committee.

Funding of ISAAC Phase Three

As with ISAAC Phase One, ISAAC Phase Three was open to any collaborator who agreed to adhere to the protocol and each centre was requested to provide it's own funding. The programme was funded by the many funding bodies throughout the world that supported the individual ISAAC centres and collaborators and their meetings. In New Zealand ISAAC was funded by:

The Health Research Council of New Zealand,
The Asthma and Respiratory Foundation of New Zealand,
The Child Health Research Foundation,
The Hawke’s Bay Medical Research Foundation,
The Waikato Medical Research Foundation,
Glaxo Wellcome New Zealand,
The NZ Lottery Board
Astra Zeneca New Zealand.

Travel grants were awarded by the Auckland Medical Research Foundation and the Maurice & Phyllis Paykel Trust.
Glaxo Wellcome International Medical Affairs supported the regional coordination and the ISAAC International Data Centre.
The ISAAC International Data Centre is currently funded grants from the BUPA Foundation, The Auckland Medical Research Foundation and The New Zealand Lotteries Commission.